# FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

> **NCT00090051** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 552 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine Phosphate
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00090051
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07-31
- **Primary completion:** 2008-07-23
- **Final completion:** 2012-05-31
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2017-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090051, "FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00090051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*